Company

Tagworks Pharmaceuticals BV

Tagworks develops antibody-drug conjugates and related technology for cancer treatment.

About

Founded in 2011, Tagworks Pharmaceuticals is based in Arnhem, Netherlands. Its pipeline includes TGW101, an antibody-drug conjugate targeting TAG72. In June 2023, the company raised USD 65 million in Series A funding co-led by Gilde Healthcare Partners and Ysios Capital Partners, with participation from Novartis Venture Fund, New Enterprise Associates and Lightstone Ventures. As of 2023, CEO Marc Robillard led the company.

1Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in